About: Rationale for the use of N‐acetylcysteine in both prevention and adjuvant therapy of COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rationale for the use of N‐acetylcysteine in both prevention and adjuvant therapy of COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rationale for the use of N‐acetylcysteine in both prevention and adjuvant therapy of COVID‐19
Creator	Balansky, Roumen De Flora, Silvio Maestra, La Sebastiano, \|
Source	Medline; PMC
abstract	COVID‐19 may cause pneumonia, acute respiratory distress syndrome, cardiovascular alterations, and multiple organ failure, which have been ascribed to a cytokine storm, a systemic inflammatory response, and an attack by the immune system. Moreover, an oxidative stress imbalance has been demonstrated to occur in COVID‐19 patients. N‐ Acetyl‐L‐cysteine (NAC) is a precursor of reduced glutathione (GSH). Due to its tolerability, this pleiotropic drug has been proposed not only as a mucolytic agent, but also as a preventive/therapeutic agent in a variety of disorders involving GSH depletion and oxidative stress. At very high doses, NAC is also used as an antidote against paracetamol intoxication. Thiols block the angiotensin‐converting enzyme 2 thereby hampering penetration of SARS‐CoV‐2 into cells. Based on a broad range of antioxidant and anti‐inflammatory mechanisms, which are herein reviewed, the oral administration of NAC is likely to attenuate the risk of developing COVID‐19, as it was previously demonstrated for influenza and influenza‐like illnesses. Moreover, high‐dose intravenous NAC may be expected to play an adjuvant role in the treatment of severe COVID‐19 cases and in the control of its lethal complications, also including pulmonary and cardiovascular adverse events.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1096/fj.202001807
bibo:pmid	32780893
has license	no-cc
sha1sum (hex)	bf0b014adbee2f36ff1c2797d0143d705de042ac
schema:url	https://doi.org/10.1096/fj.202001807
resource representing a document's title	Rationale for the use of N‐acetylcysteine in both prevention and adjuvant therapy of COVID‐19
has PubMed Central identifier	PMC7436914
has PubMed identifier	32780893
schema:publication	FASEB J
resource representing a document's body	covid:bf0b014adbee2f36ff1c2797d0143d705de042ac#body_text
is schema:about of	named entity 'acute respiratory distress syndrome' named entity 'adjuvant therapy' named entity 'ALTERATIONS' named entity 'COVID-19' named entity 'immune system' named entity 'N-acetylcysteine' named entity 'acute respiratory distress syndrome' named entity 'systemic inflammatory response' named entity 'COVID-19' named entity 'N-acetylcysteine' named entity 'interleukin' named entity 'pathogenesis' named entity 'GSH' named entity 'COVID' named entity 'mice' named entity 'metabolites' named entity 'SARS-CoV' named entity 'GSH' named entity 'influenza' named entity 'double-blind trial' named entity 'RNA viruses' named entity 'Sendai' named entity 'COVID' named entity 'unstable angina' named entity 'cardiovascular' named entity 'bronchiectasis' named entity 'chronic renal failure' named entity 'translocation' named entity 'lung disease' named entity 'α1-antitrypsin' named entity 'SARS-CoV' named entity 'NF-κB' named entity 'complement' named entity 'clinical studies' named entity 'influenza' named entity 'diffusible' named entity 'L-Cys' named entity 'HO-1' named entity 'ACE2' named entity 'multiple organ failure' named entity 'FDA' named entity 'COVID-19' named entity 'placebo group' named entity 'blood serum' named entity 'endogenous' named entity 'oxidative stress' named entity 'infarction' named entity 'oxidative stress' named entity 'ACE2' named entity 'p38' named entity 'Nrf2' named entity 'MERS-CoV' named entity 'body weight' named entity 'oxidation' named entity 'LPS' named entity 'safety profile' named entity 'immune response' named entity 'NFκB' named entity 'immune function' named entity 'COPD' named entity 'dementia' named entity 'GSH' named entity 'rate-limiting' named entity 'intravenous administration' named entity 'bronchoalveolar lavage fluid' named entity 'p38' named entity 'virus' named entity 'autoimmune diseases' named entity 'GSH' named entity 'cellular nucleus' named entity 'tumor necrosis factor-alpha' named entity 'chemotaxis' named entity 'neurogenic inflammation' named entity 'reverse transcriptase' named entity 'COVID' named entity 'cigarette smoke' named entity 'H9N2' named entity 'gene expression'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software